28
Participants
Start Date
July 31, 2007
Primary Completion Date
June 30, 2008
Study Completion Date
October 31, 2008
levetiracetam
The participants will start receiving Levetiracetam 500mg in the mornings of the first day on week 2. The dose will be titrated every third day, until the target dose of 3000mg/day is achieved by week 4. The study medication must be titrated to 3000 mg/day or to the subject's maximum tolerated dose (MTD). The physician overseeing this titration as well as all study staff will be blind to the subject's medication administration. The medication will be discontinued over a two-week period.
Placebo
VA CT Healthcare System, West Haven
National Institute on Drug Abuse (NIDA)
NIH
Yale University
OTHER